[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Toulouse\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":649},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,176,0,25,[9,42,77,105,130,160,184,215,248,268,294,316,348,369,392,413,433,461,485,513,538,559,583,601,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":21},"100631423","pilot-study-home-use-of-wearable-grasping-neuroprosthesis-in-vascular-hemiparesis-100631423",false,"NCT07500480","Pilot Study: Home Use of Wearable Grasping Neuroprosthesis in Vascular Hemiparesis","Pilot Study Evaluating the Usability and Functional Impact of Prolonged Home Use of a Wearable Grasping Neuroprosthesis in Subjects With Vascular Hemiparesis - GRASP-HOME","GRASP-HOME","Inclusion CriteriA\u002F\n\n* Adult patient who participated in and completed the GRASP-AGAIN study and achieved functional improvement through the use of NAP.\n* Motor deficit of an upper limb resulting from a single ischemic or hemorrhagic stroke, hemispheric or brainstem, confirmed by brain imaging (CT scan or MRI);\n* Brain lesion occurring more than one month prior;\n* Presence of at least one of the following two disabilities:\n\n  * Inability to actively extend the long fingers (open the hand) to actively grasp an empty glass (upper and lower diameters of 7 and 6 cm respectively, height of 12 to 15 cm, weight of 125 g, identical to the material used for the Action Research Arm Test scale) with a palmar grip, without the aid of the other hand, while the subject is able to hold the glass passively in the hand;\n  * Inability to actively extend the thumb to grasp the handle of a soup spoon (flat, like a key) without the aid of the other hand, using a thumb-index finger pulp-lateral grip (grasping task in the Wolf Motor Function Test), while the subject can passively hold the handle of a spoon or a key previously placed between the thumb and index finger;\n* Patient receiving care within the standard healthcare pathway;\n* Ability to sit in a chair and remain focused for at least 1.5 hours;\n* Free, informed, and written consent signed by the participant and the investigator (no later than the day of enrollment and before any examination required for the research);\n* Individual affiliated with or covered by a social security scheme\n\nExclusion Criteria:\n\n* The person is in labor or breastfeeding;\n* The person is pregnant, the diagnosis being guided by questioning (date of last menstrual period, desire for pregnancy, contraception) and possibly confirmed by a blood test for beta hCG;\n* Musculotendinous contractures or joint stiffness of the fingers and wrist preventing passive opening of the fingers;\n* Limited approach ability preventing the hand from being positioned in front of the abdomen (without contact) at the level of the midline sagittal plane, while the subject is seated;\n* Paretic pain in the upper limb limiting the performance of the standardized grasping task;\n* Major sensory disturbances corresponding to a Somatosensation subscore of the modified Erasmus Nottingham Sensory Assessment French version (EmNSA-F, see Appendix A) upper limb \\\u003C10\u002F44;\n* Severe aphasia with a Boston Diagnostic Severity Aphasia Examination Severity Scale score ≤ 3, see Appendix B, indicating that there may be a marked decrease in verbal fluency or ease and rapidity of comprehension, without significant limitation of expression or communication;\n* Known gestural apraxia, within the limits of the subject's motor abilities (ideomotor apraxia, ideational apraxia, dressing apraxia, or reflexive apraxia);\n* Unilateral spatial neglect demonstrated with the bell test (see Appendix B'), if the difference between omissions in the left and right visual fields is greater than or equal to 6;\n* The extensor digitorum communis and\u002For extensor pollicis longus muscles cannot be stimulated with the neuroprosthesis, meaning that sufficient extension of the long fingers and\u002For thumb for grasping tasks is not achieved with electrical stimulation well tolerated by the patient;\n* The person has a pacemaker;\n* Presence of uncontrolled epilepsy;\n* Presence of unstable cardiovascular disease (coronary artery disease, severe hypertension, heart failure);\n* Presence of a dermatological condition contraindicating the application of surface electrodes;\n* The person is participating in another research study with an ongoing exclusion period;\n* The person is under legal guardianship or conservatorship;\n* The person refuses to sign the consent form;\n* It proves impossible to provide the person with informed consent and ensure their compliance due to impaired physical and\u002For psychological health.","ALL","18 Years",{"count":21,"type":22},2,"ESTIMATED","INTERVENTIONAL",[25],"NA","Stroke is the leading cause of acquired motor disability in adults. Six months post-stroke, 50% of patients have not regained active finger extension, and 80% retain a grasping deficit, most commonly an inability to actively open the hand. This motor impairment significantly impacts daily activities, social interactions, professional life, and overall quality of life. Despite numerous treatments available in rehabilitation centers during the subacute phase, no functional assistive devices are currently usable at home. Since 2018, our team, in collaboration with the CAMIN-INRIA team, has developed a Grasp Neuroprosthesis (GNP). This device uses functional electrical stimulation to restore grasping function in hemiplegic subjects, enhancing autonomy in daily bimanual tasks. The GNP has been evaluated in hospital settings through two studies, defining preferred control modalities and demonstrating significant functional impact. Additionally, another study tested a wearable version of the GNP used autonomously at home for two months. This study showed the feasibility and functional benefits of home GNP use, provided the device is customizable to the patient's characteristics and environment. Initial results indicate improved quality of life and increased autonomy with GNP use. The wearable GNP consist of a forearm orthosis made of soft fabric, integrating an electrode array and a stimulator (CE medical marking for home use), connected via WiFi to a microprocessor positioned in a pouch. The microprocessor incorporates information from inertial measurement units and a microphone, allowing the user to control the electrical stimulator on demand. The stimulation targets the extensor muscles of the long fingers and the thumb, enabling the user to open the hand on demand. We propose extending the home use of the GNP to two patients for one year. Each subject will be followed for one year, with evaluations in a hospital setting at the beginning and end of the period, monthly follow-ups at home throughout the year, and on-demand video consultations.",[28,29],"Stroke","Réhabilitation","RECRUITING","2026-06-26",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":34},"2026-04-20",{"date":38,"type":22},"2027-04-30",{"name":40,"class":41},"University Hospital, Toulouse","OTHER",{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100644700","biological-collection-on-emerging-infectious-diseases-and-their-treatments-100644700","NCT07674550","Biological Collection on Emerging Infectious Diseases and Their Treatments","A Biological Sample Collection Established to Support Pathophysiological Research on Emerging and Potentially Emerging Infectious Diseases, as Well as Their Therapeutic Management.","COMETE","Inclusion Criteria:\n\n* Patients aged 18 years or over\n* Patients or individuals who have been exposed, are at risk of exposure, or are at risk of complications if exposed, or who are suspected of having, or are diagnosed with, an infectious disease considered to be emerging or at risk of emerging\n* Patients receiving, or likely to receive, innovative treatments for the infection (new therapeutic molecules, checkpoint inhibitors, cell therapies, etc.)\n* Patients or individuals receiving, or likely to receive, vaccines or other preventive therapeutic strategies\n* Pregnant and breastfeeding women may be included.\n\nExclusion Criteria:\n\n\\- Patients under a legal guardianship arrangement (guardianship, curatorship or court-ordered guardianship)","99 Years",{"count":52,"type":22},5300,"10 Years","OBSERVATIONAL","Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs). Advances in the treatment of cancers, malignant haematological disorders and immune-mediated inflammatory diseases are also contributing to the creation of new infectious risks among immunocompromised patient populations.\n\nThe COVID-19 pandemic has shown that structuring research prior to any outbreak is essential for the rapid implementation of responses to the emergence of an EID. The unpredictability of an EID's occurrence necessitates the planning of research projects in advance. A key element in this planning is the development of a collection of biological samples, providing a structured and immediately deployable resource for conducting pathophysiological and therapeutic research aimed at:\n\n* Analyze the biological determinants of the microbe and the resulting infection\n* Develop new tools for identification and characterization\n* Study the factors (biomarkers\u002Fsignatures) associated with individual patient susceptibility and response to treatment (personalized medicine)\n* Understand the pathophysiology of infection to identify new targets for diagnostic, curative and preventive treatment\n* Monitor the efficacy of curative and preventive treatments",[57],"Emerging Infectious Diseases and Their Treatments",[59,60,61,62,63,64,65,66],"Infectious diseases","acute respiratory infections","arboviral infections","infections of immunosuppressed patients","multi-resistant bacteria","orphan infectious diseases","disease X","new therapies","NOT_YET_RECRUITING","2026-06-24",{"date":70,"type":34},"2026-06-29",{"date":72,"type":22},"2026-06-15",{"date":74,"type":22},"2036-06-14",{"name":40,"class":41},1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":76},"100639802","platelets-and-extracorporeal-membrane-oxygenation-veno-venous-100639802","NCT07580469","Platelets and Extracorporeal Membrane Oxygenation Veno-venous","Study of PLATelet Functions and Risk Factors for Hemorrhagic Complications in Patients on Extracorporeal Membrane Oxygenation Veno-venous: Prospective Monocentric Cohort","PLAT-VV-ECMO","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)\n* Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO\n* Equipped with an arterial catheter for blood sampling\n* Ability to undergo the 4 blood draws relevant to the study\n* Receiving therapeutic anticoagulation with unfractionated heparin\n* Enrolled in a social security program or equivalent\n* No measures for Limitation and Withdrawal of Therapy have been implemented\n\nExclusion Criteria:\n\n* Minors\n* Patients under court-appointed guardianship or conservatorship\n* Pregnant or breastfeeding women\n* Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia\n* Platelet transfusion within 7 days prior to enrollment\n* Indication for immediate emergency ECMO preventing blood sampling before placement\n* Post-cardiotomy\n* Patient on antiplatelet therapy\n* Severe thrombocytopenia \\\u003C50 G\u002FL\n* Other invasive mechanical support such as Impella®, intra-aortic balloon pump, or Left Ventricular Assist Device (LVAD)",{"count":86,"type":22},40,"In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.",[89,90,91,92],"Extracorporeal Membrane Oxygenation Complication","Hemorrhage","Blood Platelet Disorder","Thrombosis",[94,95,96,97,98],"VV-ECMO","Platelets","Thrombopathy","thrombo-haemorrhagic complications","thrombo-inflammation",{"date":70,"type":34},{"date":101,"type":22},"2026-09",{"date":103,"type":22},"2028-12-31",{"name":40,"class":41},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":76},"100580671","impact-of-variation-of-oxydo-reduction-potential-in-cardiac-surgery-on-post-operative-outcome-100580671","NCT06840327","Impact of VARIation of OXYdo-reduction Potential in Cardiac Surgery on Post-operative Outcome","VARIOXY","Inclusion Criteria:\n\nPatients over 18 years of age Scheduled cardiac surgery patients undergoing bypass surgery with saphenous vein harvesting.\n\nPatients able to understand the protocol; Patients able to express non-opposition to participating in the study Patients affiliated to a social security system or equivalent.\n\nExclusion Criteria:\n\nEmergency surgery patients. Pregnant or breast-feeding women. Patients deprived of their freedom or under legal protective measures.",{"count":113,"type":22},120,"Observational, prospective, monocentric study conducted in the cardiac surgery department about biological markers to predict the short-term outcome of heart surgery patients.",[116,117],"Cardiac Surgery","Extracorporeal Circulation",[119,120,121,122,123],"extracorporeal circulation","cardiac surgery","biological markers","Redox balance","post-operative outcome",{"date":70,"type":34},{"date":126,"type":34},"2025-10-07",{"date":128,"type":22},"2027-10",{"name":40,"class":41},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":76},"100563531","combined-whole-brain-structural-and-functional-mri-for-the-prediction-of-neurological-recovery-after-cardiac-arrest-100563531","NCT06617377","Combined Whole-brain Structural and Functional MRI for the Prediction of Neurological Recovery After Cardiac Arrest","Use of Brain Structural and Functional Connectomes for the Prediction of Neurological Recovery in Coma Patients After Cardiac Arrest","ARISE","Inclusion Criteria:\n\n* Adult patients (male or female ≥ 18 years).\n* Coma, as indicated by a Glasgow Coma Scale (GCS) ≤ 8 (motor score ≤ 2) immediately after CA resuscitation and before sedation onset.\n* Persisting unconsciousness, defined as the inability to obey verbal commands, after at least 72 hours from complete withdrawal of sedation in normothermia conditions.\n* Written informed consent from patient's legal representative.\n* Affiliation or beneficiary to the French social security system.\n\nExclusion Criteria:\n\n* Brain death.\n* Coma explained by other cause than CA.\n* Likely poor neurological outcome based on early predictors, following ERC-ESCIM 2021 recommendations. In a comatose patient with GCS motor score ≤ 3 at ≥ 72 h from ROSC, in the absence of confounders, the identification of at least two of the following: bilaterally absent pupillary light and corneal reflexes at ≥ 72h, bilaterally absent N20 SSEP ≥ 24h; neuron-specific enolase (NSE) \\> 60 μg\u002Fl at 48h and\u002For 72h, status myoclonus ≤72h.\n* Decision of WLST previous to patient recruitment, based on early predictors of poor neurological outcome, age, co-morbidity, general organ function and patient's preferences.\n* Life expectancy shorter than 6 months based on pre-morbid conditions.\n* Former neurological functional disability (mRS \\> 2 before CA).\n* MRI contraindication: medical material not MRI compatible, claustrophobia\n* Known hypersensitivity to gadoteric acid, meglumin or any drug containing gadolinium\n* Severe kidney failure defined as a KDIGO score \\> 3 (glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2 or renal replacement therapy).\n* Hemodynamic shock or severe respiratory failure precluding patient's transport and MRI scanning.\n* Pregnancy or nursing woman.\n* Patient under juridical protection.",{"count":139,"type":22},263,[25],"To assess the performance of a predictive model resulting from the analysis of sMRI\u002FfMRI\u002Fcontrast-enhanced MRI-derived personalized connectomic data, as compared with standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) collected ≥ 72h from sedation withdrawal and in normothermia condition, to predict anoxoischemic coma neurological outcome at 6 months.",[143,144,145,146],"Coma","Cardiac Arrest","Disorder of Consciousness","Neurologic Disorder",[148,149,150,151,152,153],"prognosis","coma","cardiac arrest","Structural MRI","resting-state","cognitive motor dissociation",{"date":70,"type":34},{"date":156,"type":34},"2026-03-16",{"date":158,"type":22},"2029-09",{"name":40,"class":41},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":167,"sex":18,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":76},"100645018","measuring-the-evolution-of-speech-perception-in-noise-in-realistic-sound-environments-according-to-age-100645018","NCT07675941","Measuring the Evolution of Speech Perception in Noise, in Realistic Sound Environments According to Age","SI 360","Inclusion Criteria:\n\n* Children with normal hearing (average hearing thresholds at 250 Hz, 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz less than 20 dB)\n* Be between 7 and 15 years old\n* Be a native French speaker, without bilingualism\n* Have typical development, as assessed by a school level corresponding to their age;\n* No objection from at least one of the two legal guardians\n* Legal guardian registered with social security\n* Able to understand instructions and information provided\n\nExclusion Criteria:\n\n* Inability of the child to respond to tests\n* Abnormal hearing thresholds\n* Speech disorder treated by speech therapist\n* Inability to understand instructions \u002F to respond to tests\n* Neurological conditions\n* Multiple disabilities\n* Ongoing treatment that may affect alertness\n* Unstable ADHD\n* History of tympanic surgery for chronic otitis media\n* Legal impossibility",true,"7 Years","15 Years",{"count":171,"type":22},150,"In clinical settings, hearing perception is typically assessed using audiometric tests administered in a controlled environment. To date, these tests are administered in silence or in the presence of noise from fixed sources at an arbitrarily predetermined signal-to-noise ratio. These assessment situations are not representative of the functional difficulties encountered by people with hearing loss or Auditory Processing Disorder in their daily lives. In real life, \"soundscapes\" are diverse. Hearing assessment and rehabilitation should include the child's everyday environments as well as their lifestyle habits.\n\nThe Immersion 360 System (Virtual reality system) was developed specifically to virtually reproduce complex everyday sound experiences with realistic noise types and sound presentation conditions, enabling the assessment of auditory perception under test conditions similar to those encountered in daily life. Some of the sound environments offered by this innovative system have been standardized for adults. No standards exist for children, and we have limited knowledge regarding the development of speech perception skills in noise during childhood and adolescence. It seems essential to measure the age-related development of speech perception in realistic sound environments in order to establish reference data for children and adolescents.\n\nThis work will, through functional assessments of the auditory system and linguistic tests (speech perception in noise), provide a better understanding of the functional development of the central auditory system for speech perception in noise. The results collected from normo-hearing individuals in the age groups of interest will provide a clinical baseline for comparison with patients of the same age.",[174,175,176],"Noise Exposure","Normal Hearing","Child","2026-06-23",{"date":33,"type":34},{"date":180,"type":22},"2026-07",{"date":182,"type":22},"2027-07",{"name":40,"class":41},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":18,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":76},"100621222","phase-1-allogeneic-adipose-tissue-derived-stem-cells-in-alzheimer-disease-100621222","NCT07367815","Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease","Allogeneic Intraveinous Injection of Adipose Tissue Derived-mesenchymal Stem Cells in Mild to Moderate Alzheimer Disease: a Phase I\u002FII Trial","A3D","Inclusion Criteria:\n\n* Patient between 50 and 85 years old\n* AD diagnosis according to NIA-AA 2011 criteria at a mild to moderate stage :\n\nMMSE score between 14 and 26 (include) positive AD amyloid biomarker\n\n* CDR (clinical dementia rating) score ≥ 1\n* Patient with no absolute contraindications for PET or MRI scans\n* Consent signed by the patient and study partner\n* presence of primary caregiver\n* Patient with social security coverage\n\nExclusion Criteria:\n\n* Brain disease (other than AD) that may cause dementia\n* Presence of concomitant pathologies not permitting participation in the study\n* Concurrent participation in other research that may influence the testing of the A3D study\n* Carrier of a pacemaker, valve prosthesis or other internal magnetic or electronic system, history of neurosurgery or aneurysm surgery, presence of metal fragments in the eyes, brain or marrow, claustrophobia\n* PET scan performed in the previous year (research context)\n* History of cancer diagnosed within the last 5 years\n* Presence of \\> 4 brain microbleeds, a single area of superficial siderosis, or evidence of previous macrohaemorrhage assessed by brain MRI scan\n* Regular use of corticosteroids or other steroidal anti-inflammatory drugs (e. g. prednisone)\n* Presence of an autoimmune disease (e. g. rheumatoid arthritis, systemic lupus erythematosus) with the exception of psoriasis\n* Pregnant or breastfeeding woman\n* Adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision For patients who will participate in the optional adipose puncture (only carried out in the Toulouse center): Antithrombotic treatment and xylocaine allergy are prohibited.","50 Years","85 Years",{"count":195,"type":22},9,[197,198],"PHASE1","PHASE2","A3D is a phase I\u002FII clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.",[201],"Alzheimer Disease",[203,204,205,206,207],"Alzheimer disease,","phase I\u002FII,","safety,","mesenchymal stem cell,","adipose tissue","2026-06-18",{"date":177,"type":34},{"date":211,"type":34},"2026-05-07",{"date":213,"type":22},"2029-05-01",{"name":40,"class":41},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":231,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":76},"100629125","radiofrequency-ablation-versus-adrenalectomy-for-adenoma-in-patients-with-primary-aldosteronism-and-hypertension-100629125","NCT07470580","Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension","Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension: a Multicentre Prospective Randomized Study","ADERADHTA2","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Hypertension confirmed into the previous 9 months by ABPM 24h SBP\u002FDBP \\>130 and\u002For\u002F80 mmHg and\u002For diurnal SBP\u002FDBP \\> 135 and\u002For 85 mmHg and\u002For nocturnal SBP\u002FDBP \\>120 and\u002For 70 mmHg with or without antihypertensive treatment\n* Diagnosis of primary aldosteronism confirmed by hormonal assays no more than 1 year before inclusion\n* Presence of a unilateral adrenal nodule \\\u003C4 cm considered suggestive of a Conn's adenoma on an prior adrenal CT or MRI scan, no more than 1 year before inclusion\n* Adrenal venous sampling if age \\> 35 years (and according to investigator decision if age \\\u003C35 years) to look for a lateralization of secretion: cannulation was successful when adrenal\u002Fperipheral venous cortisol gradients\\>2 and lateralization was assessed by comparison of right and left adrenal venous aldosterone\u002Fcortisol ratios with a cut off value\\>4 ipsilateral to the nod side to define a positive lateralization of secretion (2) no more than 1 year before inclusion\n* nodule accessible to RFA according to the judgement of the interventional radiologist performing radiofrequency before randomisation\n* nodule accessible to surgery\n* patient willing to return for 6-month follow-up\n* adult patient able to read the information sheet and give consent to take part in the study\n* Patients affiliated to the French Health Insurance\n\nExclusion Criteria:\n\n* a negative lateralization of secretion on adrenal venous sampling\n* presence of bilateral adrenal tumours\n* contralateral or bilateral macronodular adrenal hyperplasia\n* no documented primary aldosteronism\n* Cushing's syndrome or pheochromocytoma\n* adrenal tumour \\> 4 cm\n* refusal to perform adrenal catheterisation if age \\> 35 years\n* double anti-platelet aggregation, coagulation disorders or patients treated with anticoagulant treatment that cannot be stopped\n* contraindication to anaesthesia\n* excessive proximity to sensitive adjacent organs\n* patient who has had a heart attack or stroke within the last 6 months\n* allergy to iodine\n* renal insufficiency defined as a clearance of \\\u003C30 ml\u002Fmin\n* refusal to undergo radiofrequency ablation or adrenal surgery\n* minors and patients under guardianship, curatorship or safeguard of justice\n* Inability to speak, read or write French fluently\n* patients who refuse follow-up\n* pregnant women or women wishing to become pregnant in the short term; breast-feeding\n* person taking part or having taken part in other interventional research in the previous 6 months\n* any other relevant exclusion criteria as determined by the investigator",{"count":224,"type":22},134,[25],"Primary aldosteronism (PA) is characterized by hypertension, frequent hypokalaemia, and an inappropriately high aldosterone-to-renin ratio (ARR). Aldosterone-producing adenoma (APA or Conn syndrome) is one of the main causes of primary aldosteronism. Laparoscopic (LA) total-adrenalectomy or adenoma selective is an option to normalize or at least improve blood pressure (BP) control, hypokalaemia, and normalize the ARR. However, the reported result of surgery is around 50% of clinical cure rate with an overall complication rate of 5 to 14% whereas hormonal success reached around 95%.\n\nMore recently, radiofrequency ablation (RFA) has been used for patients with primary aldosteronism and unilateral adenoma.\n\nInvestigator Team assume that treatment of unilateral PA by RFA could achieve similar efficacy to treatment by LA, with potentially less adverse events, and could be a more cost-efficient procedure.",[228,229,230],"Primary Aldosteronism Due to Conn Adenoma","Radiofrequency Ablation Treatment","Adrenalectomy",[232,233,234,235,236,237,238,239],"Primary aldosteronism","hypertension","hypokalaemia","aldosterone-to-renin ratio","Aldosterone-producing adenoma","Conn syndrome","radiofrequency ablation","adrenalectomy","2026-06-10",{"date":242,"type":34},"2026-06-11",{"date":244,"type":34},"2026-06-05",{"date":246,"type":22},"2030-06-01",{"name":40,"class":41},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":50,"enrollmentInfo":256,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":76},"100550240","clinico-biological-collection-of-bone-calcium-and-growth-plate-pathologies-100550240","NCT06444503","Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies","Creation of a Biological Collection to Study the Pathophysiology and Identify Predictive Factors for the Evolution of Bone, Calcium and Growth Plate Pathologies","OSCAR","Inclusion Criteria:\n\n* Children (from birth) with growth plate or bone pathology\n* Patients affiliated to or benefiting from a social security scheme\n* Patients able to receive information about the study and to understand the information form in order to participate in the study. This implies :\n* mastery of the French language\n* Not being subject to a restriction of rights by the judicial authorities\n* Patients or legal representatives having given their consent to participate in the study (expression of non-opposition).\n\nExclusion Criteria:\n\n* Patients under legal protection (guardianship, curatorship or safeguard of justice)\n* Pregnant or breast-feeding women",{"count":257,"type":22},350,"The aim of this project is to set up a biological and clinical collection of patients with progressive bone, calcium and growth plate pathologies.\n\nThis collection will provide a better understanding of the mechanisms involved in growth plate and bone damage in these diseases and identify factors predictive of progression and new therapeutic targets.",[260],"Bone Disorder","2026-06-03",{"date":244,"type":34},{"date":264,"type":34},"2024-09-16",{"date":266,"type":22},"2034-09-16",{"name":40,"class":41},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":76},"100640567","the-potential-of-transcutaneous-electrical-nerve-stimulation-to-improve-pain-experienced-during-posterior-branch-blocks-in-patients-with-lumbar-posterior-joint-syndrome-100640567","NCT07627490","The Potential of Transcutaneous Electrical Nerve Stimulation to Improve Pain Experienced During Posterior Branch Blocks in Patients With Lumbar Posterior Joint Syndrome","The Value of Transcutaneous Electrical Nerve Stimulation (TENS) for Improving Pain Experienced During Posterior Branch Blocks in Patients With Lumbar Posterior Joint Syndrome: a Single-center, Randomized, Double-blind, Parallel-group, Controlled, Superiority Trial","TENS-INFIDOL","Inclusion Criteria:\n\n* Chronic low back pain (lasting more than 3 months)\n* Patient followed in a Chronic Pain Unit (CETD, Toulouse University Hospital)\n* Clinical and radiological diagnosis (CT scan or MRI) of posterior joint syndrome\n* Patient with an indication for infiltration therapy, feasible under standard conditions\n\nExclusion Criteria:\n\n* Spinal surgery\n* Contraindications for TENS:\n\n  * Wearing an electronic medical device (pacemakers, defibrillators, etc.)\n  * Pregnancy\n  * Area of cutaneous anesthesia\n  * Patient with an active malignant tumor\n  * Patient with deep vein thrombosis\n  * Patient with damaged or fragile skin\n* Insulin-dependent or uncontrolled diabetes\n* Uncontrolled hypertension\n* Allergy to the local anesthetics used\n* Severe psychiatric disorder\n* Lumbar injection within the previous 6 months",{"count":277,"type":22},52,[25],"Procedural pain is inadequately managed in two-thirds of patients undergoing invasive medical procedures. Several techniques exist for managing procedural pain, but they all present implementation challenges and are not without side effects. Therefore, a new, non-pharmacological, inexpensive, and easy-to-use approach would be of significant benefit. Transcutaneous electrical nerve stimulation (TENS) for pain relief could represent this alternative. Few studies have been conducted on the benefits of TENS in managing procedural pain, for example, in shoulder arthrodistension. This project proposes to study it in the context of posterior ramus infiltration in patients eligible for this indication, in the context of chronic low back pain associated with posterior joint syndrome.",[281],"Lower Back Pain Chronic",[283,284,285],"chronic lower back pain","pain","transcutaneous electrical neurostimulation","2026-05-29",{"date":288,"type":34},"2026-06-04",{"date":290,"type":22},"2026-09-01",{"date":292,"type":22},"2028-09-01",{"name":40,"class":41},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":76},"100598754","non-interventional-study-exploring-the-composition-of-the-valvular-microbiota-of-patients-undergoing-cardiac-surgery-100598754","NCT07075601","Non-interventional Study Exploring the Composition of the Valvular Microbiota of Patients Undergoing Cardiac Surgery","BIOVALV","Inclusion Criteria:\n\n* Male or female patient.\n* Present an indication for cardiac surgery that requires explantation of the aortic valve.\n* Be able to receive information about the study process and understand the study participation information form.\n* State their non-opposition to participating in the study.\n\nExclusion Criteria:\n\n* Patients infected with HIV\n* Age under 18\n* Under court supervision, guardianship, or curatorship\n* Patients with a history of infective endocarditis.",{"count":302,"type":22},200,[25],"The prevalence of aortic valve disease is increasing, with these valvulopathies present in half of individuals over the age of 65.\n\nOberbach A. et al (1) demonstrated the presence of microbiota in 52% of cases of explanted aortic valves. One current hypothesis is the role of this microbiota in the pathophysiology of these degenerative valve diseases. This microbiota is probably not completely eradicated after resection of the native valve and implantation of a conventional prosthesis; it is even left in place during percutaneous aortic valve implantation, during which the prosthesis is deployed within the native valve. It could therefore also play a role in the occurrence of postoperative complications and the degeneration or thrombosis of a bioprosthesis.\n\nFurthermore, recent clinical and epidemiological studies have shown a link between oral infections and cardiovascular diseases. As recommended by the HAS, these patients require multidisciplinary care, involving cardiologists, cardiac surgeons and general practitioners, as well as careful oral and dental care and monitoring provided by specialists in oral pathologies and oral care. The accumulation of bacterial plaque on the surface of the tooth and certain oral bacteria causes the development of periodontal pockets which are characteristic of periodontitis. Bacteria, microbial products and inflammatory mediators produced locally can then enter the bloodstream and affect distant organs such as the cardiovascular system. The recommendations of the European Society of Cardiology are therefore to carry out regular oral and dental consultations to prevent the risk of infection. Therefore, within the Toulouse University Hospital, a care network has been set up for patients with cardiovascular pathologies, in order to improve their access to dental care, screening and management of oral diseases. For the past year, patients hospitalized in the cardiology departments have been seen in consultation in the dental department of the Toulouse University Hospital.",[306,116,307],"Valvulopathy","Microbiota","2026-05-28",{"date":310,"type":34},"2026-06-01",{"date":312,"type":34},"2025-11-19",{"date":314,"type":22},"2029-08-31",{"name":40,"class":41},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":167,"sex":18,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":327,"briefSummary":328,"conditions":329,"keywords":335,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":76},"100598718","chrono-restricted-diet-and-physical-activity-as-a-new-preventive-strategy-for-sarcopenia-in-postmenopausal-women-with-obesity-and-type-2-diabetes-100598718","NCT07075133","Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes","TIMEDIAB","Inclusion Criteria:\n\n* Post-menopausal women (amenorrhea for at least 12 months, confirmed by gonadotrophins measures)\n* Age range 45-70 years\n* T2DM diagnosed for more than 1 year\n* Subjects with T2DM treated with lifestyle control alone or associated with metformine ± DPP4 inhibitors\n* Ability to sign written informed consent before any study-specific procedure\n* Subject considered as reliable and capable of adhering to protocol\n* Subjects with Body Mass Index (BMI)≥ 30 kg\u002Fm²\n* Baseline eating period ≥ 14 h per day (as estimated by 95% eating interval)\n\nExclusion Criteria:\n\n* Subjects on T2DM injectable medication or drugs able to induce hypoglycemia (glinides, sulfonylurea)\n* Subjects with HbA1c \\> 8%\n* Subjects with any of the following medical conditions:\n\n  * Congestive cardiac failure\n  * Stage 4 chronic kidney disease (i.e. eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2)\n  * Liver cirrhosis or chronic liver disease\n  * Any medical condition that in the opinion of the investigator could jeopardize or compromise the subject's ability to participate in the study\n* Subjects with previous or present history of serious eating disorder\n* Subjects not able to understand the informed consent form or fasting diary instructions\n* Subjects currently participating or has participated in another study of an investigational medication or an investigational medical device within the last 30 days\n* Women with menopause hormone replacement therapy","45 Years","70 Years",{"count":326,"type":22},45,[25],"The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint",[330,331,332,333,334],"Obesity","Sarcopenia","Post Menopause","Type 2 Diabetes","Circadian Clock",[336,337,338,339,330,340,341],"Timing of eating","Timing of exercise","Muscle Function","Metabolic Health","Menopause","women",{"date":310,"type":34},{"date":344,"type":22},"2026-09-15",{"date":346,"type":22},"2029-07-15",{"name":40,"class":41},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":21},"100563279","study-enabling-the-collection-of-clinical-data-necessary-for-the-second-phase-of-development-of-the-glycemic-measurement-device-by-analysis-of-exhaled-air-100563279","NCT06614101","Study Enabling the Collection of Clinical Data Necessary for the Second Phase of Development of the Glycemic Measurement Device by Analysis of Exhaled Air","BOYDSENSE DATA","Inclusion Criteria:\n\n* Patient living with type 2 diabete or non-diabetic individuals characterized by overweight\u002Fobesity (Body Mass Index \\>= 25Kg\u002Fm²) , admitted in the two departments of the Toulouse University Hospital (Diabetology, Metabolic Diseases and Nutrition as well as Endocrinology, Metabolic Diseases and Nutrition).\n* Aged 18 years or more.\n* Ability to sign informed consent.\n* Affiliation to a social security scheme.\n\nExclusion Criteria:\n\n* Ongoing respiratory infection.\n* Pregnancy or breastfeeding.\n* Patient under guardianship, curatorship or safeguard of justice.",{"count":356,"type":22},235,[25],"A pilot study carried out by the company ALPHA-MOS in 2017-19 showed that the analysis of volatile organic compounds contained in exhaled air could reliably predict blood glucose levels. Subsequently, the company BOYDSense, a subsidiary of ALPHA-MOS, produced the Module In a Box prototypes of portable, non-invasive volatile organic compounds analyzers that could be equipped with an on-board algorithm estimating blood glucose levels. The Toulouse University Hospital conducted the BOYDSENSE-GM study in 2021-2023, in partnership with BOYDSense, aiming to develop the first algorithm for calculating blood glucose levels based on the analysis of the breath of 100 patients living with type 2 diabetes and to carry out a first performance test of the Module In a Box prototype in 30 additional subjects with type 2 diabetes. These recent results confirmed the potential of this innovative blood glucose measurement technology and gave the first indications about the next developments needed to improve its performances. The characteristics of the air exhaled by a human are impossible to simulate. Therefore, further development of the glucose calculation algorithm requires the production of additional clinical data, supporting the carrying out of the present study.",[333],[361,362],"Blood sugar measurement","exhaled air",{"date":310,"type":34},{"date":365,"type":34},"2024-10-11",{"date":367,"type":22},"2027-05-31",{"name":40,"class":41},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":384,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":76},"100538683","international-multicenter-project-comparing-radiofrequency-ablation-versus-implantable-defibrillator-after-well-tolerated-ventricular-tachycardia-in-ischemic-heart-disease-with-minimally-impaired-ejection-fraction-100538683","NCT06294028","International Multicenter Project Comparing Radiofrequency Ablation Versus Implantable Defibrillator After Well-tolerated Ventricular Tachycardia in Ischemic Heart Disease With Minimally Impaired Ejection Fraction","VIVA","Inclusion Criteria:\n\n* ischemic heart disease with history of infarction - LVEF\\> 35% (measured by MRI)\n* sustained monomorphic ventricular tachycardia - without history of syncope or cardiac arrest -\n* having signed informed consent\n* affiliated to a social security system\n\nExclusion Criteria:\n\n* transient regressive cause of ventricular tachycardia\n* recent myocardial infarction (\\\u003C2 months)\n* ventricular tachycardia by reentry from branch to branch\n* serious conduction disturbances (with indication of stimulation)\n* contraindication to the implantation of a defibrillator or to the performance of an ablation (life expectancy \\\u003C1 year, relevant comorbidities)\n* pregnancy\n* age \\\u003C18 years\n* Patient under legal protection, guardianship or curatorship","90 Years",{"count":378,"type":22},268,[25],"Evidence for the usefulness of the defibrillator in cases of preserved left ventricular ejection fraction and well-tolerated ventricular tachycardia (without cardiocirculatory arrest or syncope) is lacking, as no previous trials have included such patients. Additionally, sudden death in this particular population is low compared to other subgroups of patients with malignant ventricular arrhythmias.\n\nOn the other hand, numerous recent retrospective data show that ablation of ventricular tachycardia can reduce mortality, and also clearly reduces the number of recurrences in prospective studies.\n\nFinally, a very low rate of sudden death was observed in a multicenter European retrospective study that we conducted, including patients with well-tolerated ventricular tachycardia in structural heart disease with minimally impaired ejection fraction and benefiting from ablation without implantation of defibrillator.",[382,383],"Ischemic Heart Disease","Ventricular Tachycardia",[385],"Ablation",{"date":310,"type":34},{"date":388,"type":34},"2024-06-12",{"date":390,"type":22},"2029-12-31",{"name":40,"class":41},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":376,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":76},"100540114","home-grip-assistance-glove-on-the-use-of-the-upper-limb-and-compliance-factors-in-brain-injured-adults-100540114","NCT06312631","Home Grip Assistance Glove on the Use of the Upper Limb and Compliance Factors in Brain-injured Adults","Benefits of a Home Grip Assistance Glove on the Use of the Upper Limb and Compliance Factors in Brain-injured Adults: Comparative Multicenter Study","ECO-HAND-AVC","Inclusion Criteria:\n\n* Patient suffering from a motor deficit of the upper limb resulting from an ischemic or hemorrhagic stroke, hemispheric or brainstem, confirmed by brain imaging ;\n* Patient who suffered a stroke more than three months ago;\n* Patient unable to actively extend long fingers (hand opening) to voluntarily grasp an empty glass (upper and lower diameter of 7 and 6 cm respectively, height of 12 to 15 cm, weight of 125g, identical to equipment used for ARAT), with a palmar grip (cylindrical grip), while the subject can hold the previously placed glass passively in the hand;\n* Patient capable of passively opening the hand sufficient to grasp the glass when the gripping glove is put on, with the possibility of actively closing the hand;\n* Patient with the ability to put on and remove the SaeboGlove® gripping glove with the help of a third person if necessary and\u002For available.\n* Patient with a smartphone, tablet and\u002For computer compatible with video taking and teleconsultation.\n* Free, informed and signed consent by the participant and\u002For the person having guardianship and the investigator (at the latest on the day of inclusion and before any examination required by the research);\n* Person affiliated to or beneficiary of a social security system.\n\nExclusion Criteria:\n\n* Patient presenting retraction or stiffness of the fingers and wrist preventing complete extension of the long fingers and thumb, the wrist being at 15° extension;\n* Patient with moderate or severe muscular spasticity of the wrist flexors and the long and short flexors of the fingers and thumb (Modified Ashworth Scale ≥ 3);\n* Patient with limited active elbow extension, not allowing the ipsilateral knee to be reached with the hand, the subject being seated with the trunk vertical (approach limitation);\n* Patient with an active anterior shoulder elevation range of less than 15°;\n* Patient with other upper limb deficiencies likely to influence participation;\n* Patient and\u002For entourage who do not have access to teleconsultation, and\u002For can be reached remotely;\n* Patient with severe aphasia, Boston Diagnostic Aphasia Examination (BDAE) ≤ 3;\n* Presence of moderate or severe edema localized to the wrist and hand;\n* Patient allergic to Latex\n* History of upper limb surgery less than 6 months old.\n* Pregnant and\u002For breastfeeding women\n* Patient deprived of liberty (detained\u002Fincarcerated);\n* Patient under judicial protection\n* Impossibility of giving the person informed information and ensuring the subject's compliance due to impaired physical and\u002For psychological health",{"count":401,"type":22},100,[25],"On a functional level, performing the actions of daily life requires coordinated activity of the muscles of the upper limbs. The quality of motor recovery and\u002For technical assistance aimed at compensating for the movement deficit of the paretic upper limb (MSP) determines the possibilities of using the upper limb (MS) in activities of daily life.\n\nInterventions in the chronic phase of stroke aim to return home. The integration of the paretic upper limb into daily life activities is a major issue regarding the prognosis of recovery of use of the upper limb. Independence in daily life becomes an ultimate goal to take charge of.\n\nThis study focuses on a new technical aid device, standard orthosis type, expanding the range of gripping gloves: the SaeboGlove in everyday environments. These MS orthoses help improve the use and function of the MSP in post-stroke adults as well as their independence and participation in society.",[28],[406],"brain-injured adult",{"date":310,"type":34},{"date":409,"type":34},"2024-03-26",{"date":411,"type":22},"2027-12-31",{"name":40,"class":41},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":76},"100532393","neurofeedback-eeg-rehabilitation-protocol-on-motor-recovery-in-the-subacute-phase-post-stroke-custom-nf-stroke-100532393","NCT06212219","Neurofeedback-EEG Rehabilitation Protocol on Motor Recovery in the Subacute Phase Post-stroke (CUSTOM-NF-STROKE)","Impact of Personalization of a Neurofeedback-EEG Rehabilitation Protocol on Motor Recovery in the Subacute Phase Post-stroke (CUSTOM-NF-STROKE)","Inclusion Criteria:\n\n* Man, woman, over 18 years old\n* Motor deficit of the upper limb type of hemiplegia, secondary to a hemorrhagic or ischemic stroke authenticated by brain imaging (MRI or CT)\n* Post-stroke patients in the subacute phase, between 15 days and 6 months after the stroke\n* Correct or corrected vision allowing reading at a distance of 0 to 2m\n* Ability to maintain a seated position for 1 hour\n* Patient affiliated to a social security scheme or beneficiary of such a scheme\n* Informed patient having signed consent\n\nExclusion Criteria:\n\n* Minors (age \\\u003C 18 years)\n* Phasic disorder limiting comprehension corresponding to a Boston Diagnostic Aphasia Examination (BDAE) score \\\u003C 4\n* Attentional disorder not allowing sufficient attention to be maintained for 1 hour\n* History of known stroke with motor sequelae.\n* Known peripheral neurological pathology affecting the paretic upper limb.\n* Other known central neurological pathology\n* Factors hindering EEG acquisition (scalp pathology, abnormal cervico-cephalic movements, cranial metal implants)\n* Unstabilized epilepsy\n* Refusal to participate in the study\n* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision\n* Pregnant, parturient, or breastfeeding patient",{"count":421,"type":22},44,[25],"Neurofeedback (NF) is a procedure for providing direct sensory feedback (in the form of visual, auditory or tactile stimulation) to a patient about their brain activity when performing a cognitive or motor task. This NF aims to allow the patient to become aware of this brain activity and thus learn to modulate it voluntarily in order to improve the performance obtained on the task.\n\nThe aim of the study is to compare a \"standard NF\" procedure to a \"personalized NF\" procedure designed to optimize the level of patient acceptability based on the results obtained through these questionnaires.",[425],"Cerebrovascular Accident",[427],"Neurofeedback",{"date":286,"type":34},{"date":430,"type":34},"2024-01-08",{"date":411,"type":22},{"name":40,"class":41},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":444,"conditions":445,"keywords":448,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":4},"100492963","phase-3-evaluation-of-botulinum-toxin-type-a-in-the-treatment-of-buergers-disease-100492963","NCT05698979","Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease","BETOX","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. patient with Buerger's disease according to Olin criteria (ref)\n3. with digital ischemia with critical upper or lower limb ischemia criteria defined as Upper limb: pain and\u002For trophic disorders for at least 15 days AND digital pressure less than 50 mmHg Or TCPO2 30 mmHg) Or\u002Fand Lower limb: pain and\u002For trophic disorders for at least 15 days AND ankle pressure less than 50 mmHg (70 mmHg if diabetes), or 30 mmHg at the toe (50 mmHg if diabetes) or TCPO2 30 mmHg).\n4. Ability to attend study visits\n5. Ability to complete daily study agenda\n6. Ability to give free and informed consent\n7. Membership of a Social Security scheme\n\nExclusion Criteria:\n\n1. History of myasthenia gravis or Eaton-Lambert syndrome\n2. History of inflammatory myositis for less than 2 years or pre-existing motor neuron disease or superior limb neuropathy.\n3. Known allergy to botulinum toxin or cream lidocaine, albumin or inhaled nitrous oxide\u002Foxygen.\n4. Progressive infection of one hand or foot\n5. Aminoglycoside treatment\n6. Pregnant or nursing women\n7. History of vascular surgery of surgical sympathectomy of upper or lower limb\n8. Revascularization procedure considered within 3 months of inclusion\n9. Risk of major amputation within 3 months of inclusion\n10. Iloprost expected within one month of study treatment\n11. Hyperbaric chamber sessions scheduled within one month of study treatment\n12. Life expectancy less than 6 months\n13. Contraindication to one or more of the following products: BOTOX 100 UNITS ALLERGAN, LIDOCAINE\u002FPRILOCAINE 5%, cream or NITROUS OXIDE MEDICINAL\n14. Patients treated by class III anti arhythmic drugs for example amiodarone 15 ) Patient with guardians, curators, or protection of justice",{"count":441,"type":22},8,[443],"PHASE3","The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.",[446,447],"Buerger Disease","Raynaud Syndrome",[449,450,451,452,453,454],"botulinum toxin A","botox","feasibility","raynaud","buerger","tolerance",{"date":310,"type":34},{"date":457,"type":22},"2027-01-01",{"date":459,"type":22},"2028-02",{"name":40,"class":41},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":476,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":76},"100462076","localization-of-anatomical-structures-involved-in-nodal-tachycardias-by-high-density-mapping-100462076","NCT05296954","Localization of Anatomical Structures Involved in Nodal Tachycardias by High Density Mapping.","Localization of Anatomical Structures Involved in Nodal Tachycardias by High Density Mapping. Feasibility Study.","KOCH-MAPPING","Inclusion Criteria:\n\nGroup 1: Patients without heart disease presenting with reciprocal tachycardia by intra-nodal reentry.\n\nGroup 2: Control subjects, without nodal tachycardia, without heart disease, and admitted for ablation of atrial fibrillation or ventricular extrasystoles on a healthy heart and with a 3D system.\n\nExclusion Criteria:\n\n* Presence of underlying structural heart disease or history of atrial ablation or atrial tachycardia\n* Minor or protected patient\n* Patient under guardianship, curatorship or safeguard of justice",{"count":470,"type":22},20,[25],"The aim of the present work is to analyze the capacity of high resolution mapping systems to determine the precise location of the AV node and peri-nodal slow-conducting pathways, using standard recording parameters, but also off-line additional filter changes and additional techniques (conduction velocities, isochrones and dV\u002Fdt). The investigative team plan a prospective monocentric study.\n\nDetailed high resolution mapping of the Koch triangle and neighboring areas will be collected through the RHYTHMIA HDx 3D electro-anatomical mapping system and the multipolar ORION catheter. This sample will consist of 2 groups of patients: the first will include patients referred for AVNRT ablation and the second will include control patients (without AVNRT), referred for another indication requiring similar mapping system. If visualized, position of the slow pathway and AV node will be compared with the ablation areas, which will be set conventionally under fluoroscopy.",[474,475],"Atrioventricular Nodal Reentry Tachycardia","Supraventricular Tachycardia",[477,478],"Voltage mapping","Atrioventricular node mapping",{"date":310,"type":34},{"date":481,"type":34},"2022-02-04",{"date":483,"type":22},"2026-12",{"name":40,"class":41},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":76},"100455378","local-inflammation-in-arrhythmogenic-right-ventricular-cardiomyopathy-100455378","NCT05209776","Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy","LI-ARVC","Inclusion Criteria:\n\n* For cases:\n\n  * Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)\n  * Admitted for right ventricle electrophysiologic mapping\n* For controls \\* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.\n\nExclusion Criteria:\n\n* Diagnostic of systemic chronic inflammatory disease\n* Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.\n* Taking immunosuppressant or immunomodulating medications",{"count":493,"type":22},80,[25],"The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.",[497],"Arrhythmogenic Right Ventricular Dysplasia",[499,500,501,502,503,504,505,506],"Cardiac Electrophysiologic Techniques","Inflammation","Cytokines","Interleukin-1","Interleukin-6","Interleukin-10","Transforming Growth Factor beta","Tumor Necrosis Factor-alpha",{"date":310,"type":34},{"date":509,"type":34},"2022-02-01",{"date":511,"type":22},"2027-02",{"name":40,"class":41},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":521,"minAge":19,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":76},"100451275","sexual-dysfunction-in-hypertensive-women-100451275","NCT05156385","Sexual Dysfunction in Hypertensive Women","Sexual Dysfunction in Hypertensive Women According to Drug Adherence: Multicenter Cross-sectional Study","DYSFHO","Inclusion Criteria:\n\n* Women over 18,\n* Hospitalized or received in consultation for the management of hypertension treated in one of the hypertension and therapeutic, nephrology or cardiology departments participating in the study, with confirmed hypertension, treated with the following dosable antihypertensive agent(s): diltiazem, verapamil, acebutolol, atenolol, nébivolol, bisoprolol, metoprolol, propranolol, amiloride, furosemide, hydrochlorothiazide, indapamide, spironolactone, spironolactone, Lorsartan, Irbesartan, Ramipril, Perindopril, Amlodipine,\n* Having signed the informed consent form.\n* Beneficiary or affiliated to a French Social insurance\n\nExclusion Criteria:\n\n* Patients with bariatric surgery,\n* Patients under guardianship\u002Ftrusteeship\u002Fprotection of justice,\n* Patients with diagnosed and treated psychosis or depression, - Pregnant or nursing women.","FEMALE",{"count":523,"type":22},348,[25],"Several studies describe the existence of an association between sexual dysfunction and high blood pressure (hypertension), most often characterized by a decrease in the number of orgasms and the existence of dyspareunia.\n\nHypertension is a contributing factor, and nonadherence to medication could amplify it.\n\nThere are several ways to assess adherence to treatment: the use of declarative questionnaires, a method not without criticism because it is subject to the subjectivity of the declaration by the patient; and drug dosages, a standard technique, although insufficiently disseminated due to the high cost and greater weight of the survey protocols. Drug non-compliance is multifactorial. In addition, it has been shown that having undesirable drug effects and \u002F or being afraid of developing them is one of the major causes of non-compliance with antihypertensive treatments.\n\nThe investigators hypothesize that DS is significantly more common among hypertensive women treated with non-observers compared to hypertensive women treated with observers.\n\nThe main objective is to compare the prevalence of sexual dysfunction between a group of hypertensive women treated as observers and a group of hypertensive women treated as non-observers.",[527],"Hypertension",[529,530,531],"high blood pressure","antihypertensive drugs","sexual dysfunction",{"date":310,"type":34},{"date":534,"type":34},"2022-06-27",{"date":536,"type":22},"2027-07-07",{"name":40,"class":41},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":521,"minAge":19,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":551,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":76},"100425407","use-of-compression-bandages-in-the-prevention-of-post-mastectomy-lymphoceles-100425407","NCT04819542","Use of Compression Bandages in the Prevention of Post-mastectomy Lymphoceles","BANDOCELE","Inclusion Criteria:\n\n* Patients over 18 years old,\n* Undergoing mastectomy-type surgery with or without axillary dissection for breast cancer\n* Affiliated with a health insurance plan\n\nExclusion Criteria:\n\n* Recurrence of breast cancer,\n* Mastectomy with RMI (immediate breast reconstruction) at the same time of operation\n* Anticoagulant treatment at curative dose\n* Arteritis obliterans of the upper limbs,\n* Other cancer during treatment,\n* Decompensated heart failure,\n* Acute infectious episode (cellulitis, erysipelas, lymphangitis)\n* Acute deep vein thrombosis upper limb ipsilateral to mastectomy,\n* Cutaneous atrophy of the upper limb,\n* Bullous dermatoses,\n* Hyperalgesia of the shoulder\n* Inability to submit to the constraints of the protocol,\n* Impossibility for the patient to achieve self-restraint at the thoracic level\n* Pregnancy,\n* Feeding with milk\n* BMI\\> 35\n* Adult protected by law (guardianship, curatorship and safeguard of justice).\n* Anyone who is not in a position to give their consent in writing",{"count":546,"type":22},84,[25],"Lymphocele secondary to a mastectomy whether or not associated with a lymph node procedure (sentinel lymph node or axillary dissection) is an almost systematic consequence observed in the postoperative situation in this type of surgery.\n\nThis can be the source of pain, skin complications, and infection with a significant impact on the length of hospitalization for patients treated for breast cancer.\n\nThere is no consensus regarding the management of lymphocele. The placement of a compression bandage after mastectomy and \u002F or axillary dissection would allow a more efficient and rapid reduction of the lymphocele and a reduction in recurrences.\n\nThis would make it possible to reduce the duration of the wearing of the drain, which determines the length of hospitalization and reduce the recurrence of lymphoceles, the punctures of which can be one of the risk factors for secondary lymphedema.",[550],"Lymphocele",[552],"mastectomy",{"date":310,"type":34},{"date":555,"type":34},"2021-08-16",{"date":557,"type":22},"2027-11-01",{"name":40,"class":41},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":573,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":76},"100427593","treatment-of-central-airway-stenoses-using-computer-assisted-customized-3d-stents-tatum-100427593","NCT04848025","Treatment of Central Airway Stenoses Using Computer-Assisted Customized 3d Stents TATUM","Treatment of Central Airway Stenoses Using Computer-Assisted Customized 3d Stents TATUM (Three-dimensional Airway Tailored Stent Using Computer-aided Modeling)","TATUM","Inclusion Criteria:\n\n* Age \\>18 years\n* Informed consent\n* Complex, proximal and symptomatic (dyspnea, cough, peak flow \\\u003C 50%, FEV1 \\\u003C 50% or post-stenotic infection) airway stenosis\n\nExclusion Criteria:\n\n* Acute respiratory distress, mechanical ventilation\n* Contraindication to rigid bronchoscopy (severe and irreversible coagulation disorders)\n* Pregnancy",{"count":568,"type":22},30,[25],"Airway stenting is usually efficient to treat central airway obstruction but can lead to severe and potentially lethal complications (stent migration, obstructive granuloma, perforation, and hemoptysis).\n\n3D customized airway stents (computer-aided conception using CT-scan data), perfectly suited to airway anatomy, should improve the tolerance and safety of airway stenting.\n\nWe demonstrated in a previous pilot study, dedicated to patients with anatomically complex stenoses the safety of 3D patient-specific stents. These appealing results in highly complex situations suggest the need to evaluate these devices in more common situations.\n\nIn this study we aim to test our new generation stents in all patients planned for airway stenting. After computer-assisted segmentation of airways (VGStudioMAX 3.0 software), the stenosis is virtually corrected, leading to the conception of a virtual stent (AnatomikModeling, Toulouse), allowing for the fabrication of a mold using a 3D printer. The stent is then built and sterilized (NOVATECH, Berlin) and inserted during rigid bronchoscopy.\n\nClose follow up is then conducted, including clinical evaluation after one week, three, six and 12 months; spirometry at one week, 3 months, 6 months and 12 months and chest CT-scan at one week.",[572],"Airway Disease",[574,575,576],"rigid bronchoscopy","3D computer-assisted fabrication","silicon-dedicated stent",{"date":310,"type":34},{"date":579,"type":34},"2021-06-17",{"date":581,"type":22},"2029-12-30",{"name":40,"class":41},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":76},"100424245","assessment-of-the-functional-impact-of-a-close-loop-controlled-prehension-neuroprosthesis-in-post-stroke-patients-100424245","NCT04804384","Assessment of the Functional Impact of a Close-loop Controlled Prehension Neuroprosthesis in Post-stroke Patients","Assessment of the Functional Impact of a Closed-loop Controlled Prehension Neuroprosthesis in Post-stroke Patients. PREHENS-STROKE","PREHENS-STROKE","Inclusion Criteria:\n\n* Concerning the study population: Paresis of an upper limb from a single ischemic or hemorrhagic, hemispheric or brainstem stroke, as evidenced by brain imaging (CT or MRI); Stroke more than one month old; Impossibility to actively expand the fingers 2 to 5 (opening of the hand) to intentionally grab an empty glass (identical to the material used for the Action Research scale Arm Test), with a palmar grip (cylindrical grip), while the subject can hold the glass passively placed in the hand and\u002For the thumb to voluntarily grab the handle of a tablespoon (flat, like a wrench) with a key-grip (identical to that of the Wolf Motor Function Test), while the subject can hold the spoon previously placed passively between thumb and index; Ability to sit on a chair at least during 1h30.\n* Concerning legislative aspects: Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any investigation required by the research); Affiliate or beneficiary of the French health insurance system; The person is of age (at least 18 years old); Women and men are included; The patient is available for a follow-up of 5 days as part of his hospitalization performed as part of routine care.\n\nExclusion Criteria:\n\n* Concerning the study population: The person is parturient, or is breastfeeding; The person is pregnant, the diagnosis being guided by the interrogation (date of the last menstruation, desire of pregnancy, contraception) and possibly confirmed by a blood test (beta hCG); Musculotendinous retractions or joint stiffness of the fingers and wrist preventing passive opening of the hand sufficient to perform at least one of the functional tasks evaluated; Limitation of the approach which does not make it possible to carry out the task of gripping in front of the trunk, the subject sitting; Upper limb pain limiting achievement of the primary standardized grasping task; Major sensory disorders corresponding to a sub-score Somesthesia of the modified Erasmus Nottingham Sensory Assessment French version (EmNSA-F) for the upper limb \\\u003C10\u002F44; Severe aphasia with aphasia severity scale of the Boston Diagnostic Severity Aphasia Examination, indicating that there may be a clear decrease in verbal fluency or ease and speed of understanding, with no significant limitation expression or communication; Unilateral spatial negligence highlighted with the bells test if the difference between the omissions in the left and right fields is greater than or equal to 6; Extensor digitorum communis muscle and\u002For pollicis extensor longus muscle not stimulable with the neuroprosthesis, i.e. a sufficient extension of fingers and\u002For thumb for grasping tasks is not obtained with an electrical stimulation well supported by the patient.\n* Concerning the associated pathologies: The person is carrying a pacemaker; Presence of unstable epilepsy; Presence of unstable cardio-vascular disease (coronary heart disease, major hypertension, heart failure); Presence of a dermatological problem against indicating the application of surface electrodes.\n* Concerning associated treatments: The person should not receive an injection of botulinum toxin in the upper limb during the period of inclusion in the protocol, or in the 30 days prior to inclusion.\n* Concerning legislative aspects: The person is participating in another research protocol including an exclusion period still in progress; The person is under the protection of justice or guardianship; The person refuses to sign the consent; It is not possible to give the person informed information and to make sure of the subject's compliance due to impaired physical and\u002For psychological health.",{"count":568,"type":22},[25],"The aim of the PREHENS-STROKE study is to propose a functional replacement device to restore grip capacities in patients with hemiparesis after stroke, unable to actively open the hand to seize objects. The main objective is to evaluate the impact of the use of a self-controlled prehension neuroprosthesis on the ability to perform a standardized grasping task, consisting of grasping, relocating and releasing a glass (palmar grasp) or a spoon (key-pinch), compared to a condition without the use of the prehension neuroprosthesis.",[28],{"date":310,"type":34},{"date":597,"type":34},"2021-08-30",{"date":599,"type":22},"2027-12-30",{"name":40,"class":41},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":608,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":613,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":619,"locationsCount":76},"100411373","prevalence-and-significance-of-attr-aortic-valve-amyloidosis-in-degenerative-aortic-stenosis-100411373","NCT04636684","Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis","RACAMYL","Inclusion Criteria:\n\n* Patient over 18 years old\n* Degenerative aortic stenosis\n* Aortic valve replacement surgery\n* Signature of the informed consent form\n\nExclusion Criteria:\n\n* Non-degenerative aortic stenosis: bicuspid, rheumatic disease, aortic regurgitation\n* Persons under a system of legal protection for adults (guardianship, curatorship, etc.)\n* Pregnant women",{"count":401,"type":22},[25],"Cardiac amyloidosis is a restrictive cardiomyopathy with a potentially severe prognosis that can be life-threatening. It is linked in the vast majority of cases to a light chain deposition of immunoglobulin or transthyretin. Although myocardial involvement is predominant, other locations are possible: the atrioventricular conduction system, coronary arteries and valve leaflets. In systematic histological analyzes, deposits of amyloidosis infiltrating the aortic valve have been reported with a frequency of up to 74% for degenerative RA. The nature of these deposits has never been established because the immunostaining carried out all remained negative, probably due to decalcification prior to cutting. Currently, these deposits are considered to be local degenerative phenomena without clinical repercussions. However, the use of bone scintigraphy has shown a high prevalence, between 14 and 16%, of ATTR cardiac amyloidosis in patients with severe RA. The diagnosis of ATTR amyloidosis has been proven histologically in a few patients. Sequencing of the TTR gene has shown that they are mainly wild forms. In fact, the prevalence of transthyretin mutations in our local cohort is 20%.\n\nThe objective of this study is to determine by proteomic analysis based on mass spectrometry, the prevalence of ATTR aortic valve amyloidosis in patients undergoing surgical valve replacement for degenerative aortic stenosis.",[612],"Amyloidosis",[614],"ATTR aortic valve amyloidosis",{"date":310,"type":34},{"date":617,"type":34},"2020-12-01",{"date":411,"type":22},{"name":40,"class":41},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":631,"conditions":632,"keywords":638,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":4},"100637194","impact-of-topical-aromatherapy-on-postoperative-quality-of-recovery-after-lung-resection-100637194","NCT07622602","Impact of Topical Aromatherapy on Postoperative Quality of Recovery After Lung Resection","Evaluation of the Impact of Aromatherapy Applied to the Skin as a Complementary Treatment on the Quality of Recovery (QoR) Following Lung Resection","AromaQoR","Inclusion Criteria:\n\n* Adults aged 18 years or older,\n* undergoing scheduled lung resection for diagnostic or therapeutic purposes\n* able to give free, informed, signed consent (no later than the day of inclusion and before any examination required by the research)\n* person affiliated with or beneficiary of a social security system.\n\nExclusion Criteria:\n\n* Patients with chronic pain prior to surgery\n* patients undergoing daily pain relief treatment prior to surgery\n* patients using essential oils applied to the skin for pain relief.\n* In relation to aromatherapy:\n* history of allergy to essential oils\n* atopic skin\n* known allergies\n* asthma\n* pregnant or breastfeeding women\n* nut allergies (in relation to sweet almond oil)\n* individuals who are vulnerable or deprived of their liberty by judicial or administrative decision\n* patients participating in other interventional studies on pain.",{"count":629,"type":22},124,[25],"The key to early surgery recovery lies in optimal and immediate control of postoperative pain. Despite standard pain management protocols, lung resection is often associated with acute, neuropathic, or chronic pain, compounded by the side effects of morphine-based treatments. In this context, aromatherapy can provide complementary support, both to alleviate pain and to improve the quality of recovery after surgery.",[633,634,635,636,637],"Thoracic Surgical Procedures","Postoperative Recovery","Pain","Complementary Therapies","Aromatherapy",[639,637,640,641],"Quality of Recovery","Essential Oil","Thoracic surgery","2026-05-27",{"date":261,"type":34},{"date":645,"type":22},"2026-06",{"date":647,"type":22},"2028-06",{"name":40,"class":41},""]